Go to PegaPoll
PEGAPOLL · NEWS

Sellas' experimental blood cancer immunotherapy reduced risk of death in clinical trial

STAT News · 2026-11-17
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.

Sellas Life Sciences announced that its experimental immunotherapy, galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with advanced acute myeloid leukemia, successfully meeting the main goal of a Phase 3 clinical trial.

Continue in the app — vote & join in ➔
Source: STAT News · via ahirlevel.hu

Related news